Journal of the Renin-Angiotensin-Aldosterone System最新文献

英文中文

COVID-19: The race for a vaccine. COVID-19：疫苗竞赛

IF 2.9 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Journal of the Renin-Angiotensin-Aldosterone System

Pub Date : 2020-04-01 DOI: 10.1177/1470320320926902

Emily Lockey

引用次数: 0

Renal denervation: An uncertain future. 肾去神经:一个不确定的未来。

IF 2.9 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Journal of the Renin-Angiotensin-Aldosterone System

Pub Date : 2020-04-01 DOI: 10.1177/1470320320936094

Peter Sever

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). It is now more than 5 years since I wrote my first commentary on renal denervation (RDN).1 At the time, I was prompted by the contrast between the enormous enthusiasm for the technique, inspired by dramatic claims of >30 mmHg reductions in systolic blood pressure (SBP) observed in patients with resistant hypertension who had undergone RDN,2–4 and the minimal falls in blood pressure (BP) when RDN was studied in well-controlled trials, particularly those involving sham-control procedures.5–7 National bodies and international guidelines followed,8,9 which recommended a moratorium on the widespread clinical uptake of RDN until such time as the true benefits or otherwise of RDN had been evaluated in well-controlled studies, in a variety of patient subgroups with hypertension and possibly other cardiovascular conditions, including heart failure. Two important studies now deserve further commentary. SPYRAL HTN-ON MED10 was a proof-of-concept randomised trial of BP lowering with the Symplicity Spyral multielectrode renal denervation catheter and the Symplicity G3 renal denervation RF generator (Medtronic), used to provide circumferential radiofrequency ablation treatments in a spiral pattern in the four quadrants of the renal artery and branch vessels. The control group received a sham procedure. A total of 467 patients were recruited into this trial, and subsequently 80 with uncontrolled BP (office SBP 150–180 mmHg, a 24-hour ambulatory SBP between 140 and 170 mmHg) and receiving one to three antihypertensive drugs were randomised to RDN or sham procedure. The primary efficacy end point was change from baseline ambulatory BP at 6 months. After 6 months, baseline-adjusted treatment differences between the RDN and sham control groups were −7.0/−4.3 mmHg for 24-hour ambulatory BP and −6.6/−4.2 mmHg for office BP in favour of RDN. Both results were statistically significant. No procedural or other adverse events were reported. In SPYRAL HTN-OFF MED,11 331 patients with an office SBP between 150 and 180 mmHg were randomly assigned RDN using the same procedure as for the ontreatment trial or sham control. The primary efficacy end point was baseline-adjusted change in 24-hour SBP at 3 months. The treatment differences between the two groups at 3 months in favour of RDN were 3.9 mmHg for 24-hour SBP and 6.5 mmHg for office SBP. Both differences were statistically significant. Again, no procedural or other adverse events were reported. Thus, after more than a decade, RDN comes of age. The sponsors of these trials are to be co

{"title":"Renal denervation: An uncertain future.","authors":"Peter Sever","doi":"10.1177/1470320320936094","DOIUrl":"https://doi.org/10.1177/1470320320936094","url":null,"abstract":"Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). It is now more than 5 years since I wrote my first commentary on renal denervation (RDN).1 At the time, I was prompted by the contrast between the enormous enthusiasm for the technique, inspired by dramatic claims of >30 mmHg reductions in systolic blood pressure (SBP) observed in patients with resistant hypertension who had undergone RDN,2–4 and the minimal falls in blood pressure (BP) when RDN was studied in well-controlled trials, particularly those involving sham-control procedures.5–7 National bodies and international guidelines followed,8,9 which recommended a moratorium on the widespread clinical uptake of RDN until such time as the true benefits or otherwise of RDN had been evaluated in well-controlled studies, in a variety of patient subgroups with hypertension and possibly other cardiovascular conditions, including heart failure. Two important studies now deserve further commentary. SPYRAL HTN-ON MED10 was a proof-of-concept randomised trial of BP lowering with the Symplicity Spyral multielectrode renal denervation catheter and the Symplicity G3 renal denervation RF generator (Medtronic), used to provide circumferential radiofrequency ablation treatments in a spiral pattern in the four quadrants of the renal artery and branch vessels. The control group received a sham procedure. A total of 467 patients were recruited into this trial, and subsequently 80 with uncontrolled BP (office SBP 150–180 mmHg, a 24-hour ambulatory SBP between 140 and 170 mmHg) and receiving one to three antihypertensive drugs were randomised to RDN or sham procedure. The primary efficacy end point was change from baseline ambulatory BP at 6 months. After 6 months, baseline-adjusted treatment differences between the RDN and sham control groups were −7.0/−4.3 mmHg for 24-hour ambulatory BP and −6.6/−4.2 mmHg for office BP in favour of RDN. Both results were statistically significant. No procedural or other adverse events were reported. In SPYRAL HTN-OFF MED,11 331 patients with an office SBP between 150 and 180 mmHg were randomly assigned RDN using the same procedure as for the ontreatment trial or sham control. The primary efficacy end point was baseline-adjusted change in 24-hour SBP at 3 months. The treatment differences between the two groups at 3 months in favour of RDN were 3.9 mmHg for 24-hour SBP and 6.5 mmHg for office SBP. Both differences were statistically significant. Again, no procedural or other adverse events were reported. Thus, after more than a decade, RDN comes of age. The sponsors of these trials are to be co","PeriodicalId":17330,"journal":{"name":"Journal of the Renin-Angiotensin-Aldosterone System","volume":"21 2","pages":"1470320320936094"},"PeriodicalIF":2.9,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1470320320936094","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38074434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of angiotensin-converting enzyme insertion/deletion (ACE I/D) and angiotensinogen (AGT M235T) polymorphisms with the risk of obesity in a Tunisian population. 突尼斯人群中血管紧张素转换酶插入/缺失(ACE I/D)和血管紧张素原(AGT M235T)多态性与肥胖风险的关联

IF 2.9 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Journal of the Renin-Angiotensin-Aldosterone System

Pub Date : 2020-04-01 DOI: 10.1177/1470320320907820

Wided Khamlaoui, Sounira Mehri, Sonia Hammami, Roberto Elosua, Mohamed Hammami

Objective: This study aims to determine whether genetic variants in ACE I/D and AGT M235T are associated with overweight-obesity and body mass index (BMI) in a Tunisian population.

Methods: We designed an age- and sex-matched case-control study. The height and weight were measured and BMI was calculated. A total of 259 overweight-obese patients and 369 healthy controls were genotyped for the ACE I/D and AGT M235T genes using polymerase chain reaction and restriction fragment length polymorphism.

Results: ACE I/D and AGT M235T genes were associated with BMI, waist circumference and overweight-obesity (p⩽0.001). In an additive model, the I and the M alleles in ACE and AGT variants, respectively, were associated with a lower BMI: -1.45 and -2.29 units, respectively. ACE I/D genotypes were associated with dyslipidemia; AGT M235T genotypes with dyslipidemia and total cholesterol.

Conclusion: These data suggest that variations in ACE I/D and AGT M235T affect the risk of overweight-obesity, BMI and dyslipidemia, and could point to a key molecular pathway of metabolic syndrome and its related comorbidities.

目的:本研究旨在确定突尼斯人群中ACE I/D和AGT M235T的遗传变异是否与超重肥胖和体重指数(BMI)相关。方法:我们设计了一项年龄和性别匹配的病例对照研究。测量身高、体重，计算BMI。采用聚合酶链反应和限制性片段长度多态性对259例超重肥胖患者和369名健康对照进行了ACE I/D和AGT M235T基因分型。结果:ACE I/D和AGT M235T基因与BMI、腰围和超重肥胖相关(p < 0.001)。在加性模型中，ACE和AGT变体中的I和M等位基因分别与较低的BMI相关:分别为-1.45和-2.29单位。ACE I/D基因型与血脂异常相关;AGT M235T基因型与血脂异常和总胆固醇。结论:这些数据提示ACE I/D和AGT M235T的变化影响超重肥胖、BMI和血脂异常的风险，并可能指出代谢综合征及其相关合并症的关键分子途径。

{"title":"Association of angiotensin-converting enzyme insertion/deletion (ACE I/D) and angiotensinogen (AGT M235T) polymorphisms with the risk of obesity in a Tunisian population.","authors":"Wided Khamlaoui, Sounira Mehri, Sonia Hammami, Roberto Elosua, Mohamed Hammami","doi":"10.1177/1470320320907820","DOIUrl":"https://doi.org/10.1177/1470320320907820","url":null,"abstract":"Objective: This study aims to determine whether genetic variants in ACE I/D and AGT M235T are associated with overweight-obesity and body mass index (BMI) in a Tunisian population.Methods: We designed an age- and sex-matched case-control study. The height and weight were measured and BMI was calculated. A total of 259 overweight-obese patients and 369 healthy controls were genotyped for the ACE I/D and AGT M235T genes using polymerase chain reaction and restriction fragment length polymorphism.Results: ACE I/D and AGT M235T genes were associated with BMI, waist circumference and overweight-obesity (p⩽0.001). In an additive model, the I and the M alleles in ACE and AGT variants, respectively, were associated with a lower BMI: -1.45 and -2.29 units, respectively. ACE I/D genotypes were associated with dyslipidemia; AGT M235T genotypes with dyslipidemia and total cholesterol.Conclusion: These data suggest that variations in ACE I/D and AGT M235T affect the risk of overweight-obesity, BMI and dyslipidemia, and could point to a key molecular pathway of metabolic syndrome and its related comorbidities.","PeriodicalId":17330,"journal":{"name":"Journal of the Renin-Angiotensin-Aldosterone System","volume":"21 2","pages":"1470320320907820"},"PeriodicalIF":2.9,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1470320320907820","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37891625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Cardiovascular disease, heart failure and COVID-19. 心血管疾病、心力衰竭和 COVID-19。

IF 2.1 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Journal of the Renin-Angiotensin-Aldosterone System

Pub Date : 2020-04-01 DOI: 10.1177/1470320320926903

Luca Faconti, Philip J Chowienczyk, Ajay M Shah

引用次数: 0

Ramipril pretreatment worsened renal injury and survival despite a reduction in renal inflammation in experimentally induced sepsis in mice. 雷米普利预处理加重了实验性脓毒症小鼠的肾损伤和生存，尽管减少了肾脏炎症。

IF 2.9 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Journal of the Renin-Angiotensin-Aldosterone System

Pub Date : 2020-04-01 DOI: 10.1177/1470320320923977

Tzvetanka Bondeva, Katrin Schindler, Claudia Schindler, Gunter Wolf

Introduction: The angiotensin converting enzyme inhibitor ramipril is a standard antihypertensive therapy for many patients. Because angiotensin II may promote inflammation, we were interested in whether basal pretreatment with ramipril may modify renal function and inflammation as well as systemic outcome in experimentally induced sepsis in mice.

Material and methods: Ramipril (10 mg/kg/day) pretreatment or placebo (NaCl) was given intraperitoneally for 5 days to C57BL6/J mice, followed by either sham operation or cecal ligation and puncture sepsis induction. Real-time polymerase chain reaction and immunological stains were used to evaluate renal gene and protein expression, respectively. Plasma creatinine, neutrophil-gelatinase associated lipocalin, and blood urea nitrogen were used as markers for renal function. A clinical severity score was determined.

Results: Administration of ramipril before cecal ligation and puncture surgery was associated with reduced renal inflammation but did not improved renal function and structure and even worsened the clinical status of septic mice.

Conclusions: The data suggest that the effects of ramipril pretreatment are complex. Additional studies including monitoring of hemodynamic parameters are necessary to elucidate the exact mechanism(s) of this observation. In addition, the timing of the ramipril administration could be of importance.

血管紧张素转换酶抑制剂雷米普利是许多患者的标准降压药物。由于血管紧张素II可能促进炎症，我们对雷米普利基础预处理是否可能改变实验性脓毒症小鼠的肾功能、炎症和全身结局感兴趣。材料与方法:C57BL6/J小鼠腹腔注射雷米普利(10 mg/kg/天)预处理或安慰剂(NaCl) 5 d，假手术或盲肠结扎穿刺诱导脓毒症。实时聚合酶链反应和免疫染色分别检测肾脏基因和蛋白的表达。血浆肌酐、中性粒细胞-明胶酶相关脂钙蛋白、血尿素氮作为肾功能指标。确定临床严重程度评分。结果:盲肠结扎穿刺手术前给予雷米普利与减轻肾脏炎症有关，但并未改善肾脏功能和结构，甚至恶化了脓毒症小鼠的临床状况。结论:资料提示雷米普利预处理的效果是复杂的。需要进一步的研究，包括监测血流动力学参数，以阐明这种观察的确切机制。此外，雷米普利给药的时机也很重要。

{"title":"Ramipril pretreatment worsened renal injury and survival despite a reduction in renal inflammation in experimentally induced sepsis in mice.","authors":"Tzvetanka Bondeva, Katrin Schindler, Claudia Schindler, Gunter Wolf","doi":"10.1177/1470320320923977","DOIUrl":"https://doi.org/10.1177/1470320320923977","url":null,"abstract":"Introduction: The angiotensin converting enzyme inhibitor ramipril is a standard antihypertensive therapy for many patients. Because angiotensin II may promote inflammation, we were interested in whether basal pretreatment with ramipril may modify renal function and inflammation as well as systemic outcome in experimentally induced sepsis in mice.Material and methods: Ramipril (10 mg/kg/day) pretreatment or placebo (NaCl) was given intraperitoneally for 5 days to C57BL6/J mice, followed by either sham operation or cecal ligation and puncture sepsis induction. Real-time polymerase chain reaction and immunological stains were used to evaluate renal gene and protein expression, respectively. Plasma creatinine, neutrophil-gelatinase associated lipocalin, and blood urea nitrogen were used as markers for renal function. A clinical severity score was determined.Results: Administration of ramipril before cecal ligation and puncture surgery was associated with reduced renal inflammation but did not improved renal function and structure and even worsened the clinical status of septic mice.Conclusions: The data suggest that the effects of ramipril pretreatment are complex. Additional studies including monitoring of hemodynamic parameters are necessary to elucidate the exact mechanism(s) of this observation. In addition, the timing of the ramipril administration could be of importance.","PeriodicalId":17330,"journal":{"name":"Journal of the Renin-Angiotensin-Aldosterone System","volume":"21 2","pages":"1470320320923977"},"PeriodicalIF":2.9,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1470320320923977","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37946693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Genetic association study of prolylcarboxypeptidase polymorphisms with susceptibility to essential hypertension in the Yi minority of China: A case-control study based on an isolated population. 中国彝族人群脯氨酸羧基肽酶多态性与原发性高血压易感性的遗传关联研究:基于孤立人群的病例对照研究

IF 2.9 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Journal of the Renin-Angiotensin-Aldosterone System

Pub Date : 2020-04-01 DOI: 10.1177/1470320320919586

Yanrui Wu, Hongju Yang, Chunjie Xiao

Objective: Prolylcarboxypeptidase (PRCP) is a negative regulator of the pressor actions of the renin-angiotensin-aldosterone system. It is also involved in the kallikrein-kinin system. This gene has an important role in blood pressure (BP) regulation.

Methods: A case-control study was performed for 615 Yi participants (303 cases and 312 controls) from a remote mountainous area in Yunnan Province of China. For the PRCP gene, 11 tag single-nucleotide polymorphisms were genotyped using the polymerase chain reaction-restriction fragment length polymorphism method.

Results: The PRCP gene rs12290550 was associated with the occurrence of essential hypertension (EH) and BP traits. Logistic regression analysis indicated that the rs12290550 T allele was significantly linked to the risk of EH (odds ratio (OR) = 1.85, 95% confidence interval (CI) 1.44-2.39, p = 0.2 × 10^-5). Under Bonferroni correction, the H7 TAGCACTAACA haplotype containing the risk allele rs12290550 T increased the risk of EH (OR = 4.53, 95% CI 2.29-8.93, p = 0.2×10^-5).

Conclusions: The findings of this study demonstrate the strong association of the PRCP gene with EH. rs12290550 may be a useful genetic predictor of EH in the Yi minority.

目的:脯氨酸羧肽酶(PRCP)是肾素-血管紧张素-醛固酮系统升压作用的负调节因子。它也参与钾激肽-激肽系统。该基因在调节血压(BP)中起重要作用。方法:对云南省偏远山区615名彝族受试者(303例，312例对照)进行病例对照研究。对于PRCP基因，采用聚合酶链反应-限制性片段长度多态性方法对11个标签单核苷酸多态性进行了基因分型。结果:PRCP基因rs12290550与原发性高血压(EH)的发生及BP特征相关。Logistic回归分析显示，rs12290550 T等位基因与EH风险显著相关(优势比(OR) = 1.85, 95%置信区间(CI) 1.44 ~ 2.39, p = 0.2 × 10-5)。经Bonferroni校正，含有风险等位基因rs12290550 T的H7 TAGCACTAACA单倍型增加了EH的风险(OR = 4.53, 95% CI 2.29-8.93, p = 0.2×10-5)。结论:本研究结果表明PRCP基因与EH有很强的相关性。rs12290550可能是彝族EH的一个有用的遗传预测因子。

{"title":"Genetic association study of prolylcarboxypeptidase polymorphisms with susceptibility to essential hypertension in the Yi minority of China: A case-control study based on an isolated population.","authors":"Yanrui Wu, Hongju Yang, Chunjie Xiao","doi":"10.1177/1470320320919586","DOIUrl":"https://doi.org/10.1177/1470320320919586","url":null,"abstract":"Objective: Prolylcarboxypeptidase (PRCP) is a negative regulator of the pressor actions of the renin-angiotensin-aldosterone system. It is also involved in the kallikrein-kinin system. This gene has an important role in blood pressure (BP) regulation.Methods: A case-control study was performed for 615 Yi participants (303 cases and 312 controls) from a remote mountainous area in Yunnan Province of China. For the PRCP gene, 11 tag single-nucleotide polymorphisms were genotyped using the polymerase chain reaction-restriction fragment length polymorphism method.Results: The PRCP gene rs12290550 was associated with the occurrence of essential hypertension (EH) and BP traits. Logistic regression analysis indicated that the rs12290550 T allele was significantly linked to the risk of EH (odds ratio (OR) = 1.85, 95% confidence interval (CI) 1.44-2.39, p = 0.2 × 10-5). Under Bonferroni correction, the H7 TAGCACTAACA haplotype containing the risk allele rs12290550 T increased the risk of EH (OR = 4.53, 95% CI 2.29-8.93, p = 0.2×10-5).Conclusions: The findings of this study demonstrate the strong association of the PRCP gene with EH. rs12290550 may be a useful genetic predictor of EH in the Yi minority.","PeriodicalId":17330,"journal":{"name":"Journal of the Renin-Angiotensin-Aldosterone System","volume":"21 2","pages":"1470320320919586"},"PeriodicalIF":2.9,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1470320320919586","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37970984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to pediatric asthma: A meta-analysis. 血管紧张素转换酶插入/缺失多态性与儿童哮喘易感性:一项荟萃分析

IF 2.9 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Journal of the Renin-Angiotensin-Aldosterone System

Pub Date : 2020-04-01 DOI: 10.1177/1470320320923475

Zhengyang Shao, Haili Jin, Hong Sun, Chenxia Dong, Binbin Xu, Lu Zhan

Objective: The correlation of the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism with pediatric asthma risk was assessed in this meta-analysis.

Methods: PubMed, Web of Science, Embase and CNKI databases were systematically searched for relevant literature, followed by application of odds ratios (OR) along with 95% confidence interval (CI) for determining the strength of relationship.

Results: Seven articles with 802 cases and 632 controls fulfilled the inclusion criteria. As a result, the ACE I/D polymorphism was related to elevated pediatric asthma risk (D vs I: OR = 1.87, 95% CI = 1.59-2.20; dominant model: OR =1.53, 95% CI = 1.28-1.81; recessive model: OR =1.54, 95% CI = 1.28-1.85; DD vs II: OR =2.95, 95% CI = 2.19-3.98; DI vs II: OR = 0.96, 95% CI = 0.78-1.19). Subgroup analysis stratified by race revealed significant interrelation in Asians.

Conclusion: This meta-analysis demonstrated that the ACE I/D polymorphism might be related to the risk of pediatric asthma.

目的:本荟萃分析评估血管紧张素转换酶(ACE)插入/缺失(I/D)多态性与儿童哮喘风险的相关性。方法:系统检索PubMed、Web of Science、Embase和CNKI数据库相关文献，应用比值比(OR)和95%置信区间(CI)确定相关性强弱。结果:7篇文章802例，对照632例符合纳入标准。因此，ACE I/D多态性与儿童哮喘风险升高有关(D / I: OR = 1.87, 95% CI = 1.59-2.20;优势模型:OR =1.53, 95% CI = 1.28-1.81;隐性模型:OR =1.54, 95% CI = 1.28 ~ 1.85;DD vs II: OR =2.95, 95% CI = 2.19-3.98;DI vs II: OR = 0.96, 95% CI = 0.78-1.19)。按种族分层的亚组分析显示亚洲人有显著的相关性。结论:本荟萃分析表明，ACE I/D多态性可能与儿童哮喘的风险有关。

{"title":"Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to pediatric asthma: A meta-analysis.","authors":"Zhengyang Shao, Haili Jin, Hong Sun, Chenxia Dong, Binbin Xu, Lu Zhan","doi":"10.1177/1470320320923475","DOIUrl":"https://doi.org/10.1177/1470320320923475","url":null,"abstract":"Objective: The correlation of the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism with pediatric asthma risk was assessed in this meta-analysis.Methods: PubMed, Web of Science, Embase and CNKI databases were systematically searched for relevant literature, followed by application of odds ratios (OR) along with 95% confidence interval (CI) for determining the strength of relationship.Results: Seven articles with 802 cases and 632 controls fulfilled the inclusion criteria. As a result, the ACE I/D polymorphism was related to elevated pediatric asthma risk (D vs I: OR = 1.87, 95% CI = 1.59-2.20; dominant model: OR =1.53, 95% CI = 1.28-1.81; recessive model: OR =1.54, 95% CI = 1.28-1.85; DD vs II: OR =2.95, 95% CI = 2.19-3.98; DI vs II: OR = 0.96, 95% CI = 0.78-1.19). Subgroup analysis stratified by race revealed significant interrelation in Asians.Conclusion: This meta-analysis demonstrated that the ACE I/D polymorphism might be related to the risk of pediatric asthma.","PeriodicalId":17330,"journal":{"name":"Journal of the Renin-Angiotensin-Aldosterone System","volume":"21 2","pages":"1470320320923475"},"PeriodicalIF":2.9,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1470320320923475","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37990398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy. 血管紧张素II型1受体阻滞剂有利于影响糖尿病肾病患者肾血管紧张素II和MAS受体的表达。

IF 2.9 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Journal of the Renin-Angiotensin-Aldosterone System

Pub Date : 2020-04-01 DOI: 10.1177/1470320320919607

Ye-Ping Ma, Yue Yang, Shi-Min Jiang, Lin Liu, Zheng Zhang, Yi-Ning Wang, Gu-Ming Zou, Wen-Ge Li

Introduction: The aims of this study were to assess the renal expression of angiotensin II type 1 receptor (AT1R), angiotensin II type 2 receptor (AT2R), and MAS receptor in human type 2 diabetic nephropathy (DN).

Materials and methods: In total, 115 patients diagnosed with DN by renal biopsy were enrolled in this study. The protein expression levels of the AT1R, AT2R, and MAS receptors were assessed by immunohistochemistry.

Results: The protein expression levels of AT1R, AT2R, and MAS receptor in the renal biopsy tissue were correlated with the pathologic classification of DN. Tubulointerstitial AT1R expression in patients of class IIb was significantly stronger than control samples (p < 0.05). Expression of AT2R and MAS receptors were highest with class IIb DN patients. When DN patients were treated with AT1R blocker (ARB), the expression of AT1R was downregulated (p < 0.05), and the MAS receptor was upregulated in tubular interstitial (p < 0.05).

Conclusions: Our results directly observed that renal expression levels of AT1R increase during the early stages of DN, ARB reducing AT1R while increasing MAS receptor. Therefore, ARB should be used as soon as possible in patients with DN.

简介:本研究的目的是评估血管紧张素II型1受体(AT1R)、血管紧张素II型2受体(AT2R)和MAS受体在人2型糖尿病肾病(DN)中的肾脏表达。材料与方法:本研究共纳入115例经肾活检诊断为DN的患者。免疫组织化学检测AT1R、AT2R和MAS受体蛋白表达水平。结果:肾活检组织中AT1R、AT2R、MAS受体蛋白表达水平与DN病理分型相关。IIb类患者的管间质AT1R表达明显强于对照组(p < 0.05)。AT2R和MAS受体在IIb型DN患者中表达最高。DN患者在接受AT1R阻滞剂(ARB)治疗时，AT1R表达下调(p < 0.05)，肾小管间质MAS受体表达上调(p < 0.05)。结论:我们的研究结果直接观察到肾脏AT1R表达水平在DN早期升高，ARB降低AT1R而增加MAS受体。因此，DN患者应尽早使用ARB。

{"title":"Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy.","authors":"Ye-Ping Ma, Yue Yang, Shi-Min Jiang, Lin Liu, Zheng Zhang, Yi-Ning Wang, Gu-Ming Zou, Wen-Ge Li","doi":"10.1177/1470320320919607","DOIUrl":"https://doi.org/10.1177/1470320320919607","url":null,"abstract":"Introduction: The aims of this study were to assess the renal expression of angiotensin II type 1 receptor (AT1R), angiotensin II type 2 receptor (AT2R), and MAS receptor in human type 2 diabetic nephropathy (DN).Materials and methods: In total, 115 patients diagnosed with DN by renal biopsy were enrolled in this study. The protein expression levels of the AT1R, AT2R, and MAS receptors were assessed by immunohistochemistry.Results: The protein expression levels of AT1R, AT2R, and MAS receptor in the renal biopsy tissue were correlated with the pathologic classification of DN. Tubulointerstitial AT1R expression in patients of class IIb was significantly stronger than control samples (p < 0.05). Expression of AT2R and MAS receptors were highest with class IIb DN patients. When DN patients were treated with AT1R blocker (ARB), the expression of AT1R was downregulated (p < 0.05), and the MAS receptor was upregulated in tubular interstitial (p < 0.05).Conclusions: Our results directly observed that renal expression levels of AT1R increase during the early stages of DN, ARB reducing AT1R while increasing MAS receptor. Therefore, ARB should be used as soon as possible in patients with DN.","PeriodicalId":17330,"journal":{"name":"Journal of the Renin-Angiotensin-Aldosterone System","volume":"21 2","pages":"1470320320919607"},"PeriodicalIF":2.9,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1470320320919607","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37902456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

COVID-19 and hypertension. COVID-19和高血压。

IF 2.9 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Journal of the Renin-Angiotensin-Aldosterone System

Pub Date : 2020-04-01 DOI: 10.1177/1470320320927851

Spoorthy Kulkarni, Bernadette L Jenner, Ian Wilkinson

Infection with SARS-Cov-2 is the causative agent of coronavirus disease 2019 (COVID-19), which the WHO has described as a pandemic. As of July 27th, 2020, this disease has killed more than 16.3 million people worldwide and it appears that underlying cardiovascular disease constitutes substantial comorbidity correlated with the clinical decline and adverse outcomes in COVID-19 patients. Preliminary reports stated that hypertension may be associated with increased risk of SARS-Cov-2 infection but it now appears that older age and hypertension-related comorbidities somewhat confound this relationship. However, following the initial findings of using RAAS blockers with a higher risk of SARS-Cov-2 infection and a more serious course of COVID-19, it is now recognized that no solid scientific results are available in humans to support them. The application of RAAS blockers care in patients with appropriate indications are widely recommended by major international research organizations.

引用次数: 45

Effects of irbesartan on myocardial injury in diabetic rats: The role of NLRP3/ASC/Caspase-1 pathway. 厄贝沙坦对糖尿病大鼠心肌损伤的影响:NLRP3/ASC/Caspase-1通路的作用。

IF 2.9 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Journal of the Renin-Angiotensin-Aldosterone System

Pub Date : 2020-04-01 DOI: 10.1177/1470320320926049

Li Rong, Shuo Sun, Feiyu Zhu, Qingmei Xu, Hui Li, Qin Gao, Wei Zhang, Bi Tang, Heng Zhang, Hongju Wang, Pinfang Kang

To observe the mechanism of myocardial injury in diabetic rats after irbesartan intervention and analyze the role of nucleotide binding oligomerization domain-like receptor protein 3 (NLRP3) inflammatory pathway. The experiment was divided into four groups: normal control group (CON), high glucose and high caloric diet group (HC), diabetes group (DM) and diabetes+irbesartan group (DM+Ir). Compared with CON group, in HC group, triglyceride, total cholesterol and fasting blood glucose levels were increased; however, there was no significant difference of the cardiac function, the degree of myocardial fibrosis, NLRP3, ASC, Caspase-1 mRNA and protein expressions and the releasing of inflammatory factors interleukin (IL)-1β and IL-18. Compared with HC group, in DM group, triglyceride, total cholesterol, fasting blood glucose, IL-1β and IL-18 levels, NLRP3, ASC, Caspase-1 mRNA and protein expressions and the degree of myocardial fibrosis were increased, but the cardiac function was decreased. Compared with DM group, there were no changes in total cholesterol and fasting blood glucose, the degree of myocardial fibrosis cardiac function was attenuated, NLRP3, ASC, Caspase-1 expressions, IL-1β and IL-18 levels were reduced in DM+Ir group. The results suggested that irbesartan may exert myocardial protection by inhibiting the expression of the NLRP3/ASC/Caspase-1 pathway in diabetic rats.

观察厄贝沙坦干预后糖尿病大鼠心肌损伤的机制，分析核苷酸结合寡聚结构域样受体蛋白3 (NLRP3)炎症通路的作用。实验分为4组:正常对照组(CON)、高糖高热量饮食组(HC)、糖尿病组(DM)和糖尿病+厄贝沙坦组(DM+Ir)。与CON组比较，HC组大鼠甘油三酯、总胆固醇、空腹血糖水平升高;心功能、心肌纤维化程度、NLRP3、ASC、Caspase-1 mRNA及蛋白表达、炎症因子白细胞介素(IL)-1β、IL-18的释放差异无统计学意义。与HC组比较，DM组大鼠甘油三酯、总胆固醇、空腹血糖、IL-1β、IL-18水平、NLRP3、ASC、Caspase-1 mRNA及蛋白表达升高，心肌纤维化程度升高，心功能降低。与DM组比较，DM+Ir组大鼠总胆固醇、空腹血糖无明显变化，心肌纤维化程度、心功能减弱，NLRP3、ASC、Caspase-1表达及IL-1β、IL-18水平降低。提示厄贝沙坦可能通过抑制糖尿病大鼠NLRP3/ASC/Caspase-1通路的表达发挥心肌保护作用。

{"title":"Effects of irbesartan on myocardial injury in diabetic rats: The role of NLRP3/ASC/Caspase-1 pathway.","authors":"Li Rong, Shuo Sun, Feiyu Zhu, Qingmei Xu, Hui Li, Qin Gao, Wei Zhang, Bi Tang, Heng Zhang, Hongju Wang, Pinfang Kang","doi":"10.1177/1470320320926049","DOIUrl":"https://doi.org/10.1177/1470320320926049","url":null,"abstract":"To observe the mechanism of myocardial injury in diabetic rats after irbesartan intervention and analyze the role of nucleotide binding oligomerization domain-like receptor protein 3 (NLRP3) inflammatory pathway. The experiment was divided into four groups: normal control group (CON), high glucose and high caloric diet group (HC), diabetes group (DM) and diabetes+irbesartan group (DM+Ir). Compared with CON group, in HC group, triglyceride, total cholesterol and fasting blood glucose levels were increased; however, there was no significant difference of the cardiac function, the degree of myocardial fibrosis, NLRP3, ASC, Caspase-1 mRNA and protein expressions and the releasing of inflammatory factors interleukin (IL)-1β and IL-18. Compared with HC group, in DM group, triglyceride, total cholesterol, fasting blood glucose, IL-1β and IL-18 levels, NLRP3, ASC, Caspase-1 mRNA and protein expressions and the degree of myocardial fibrosis were increased, but the cardiac function was decreased. Compared with DM group, there were no changes in total cholesterol and fasting blood glucose, the degree of myocardial fibrosis cardiac function was attenuated, NLRP3, ASC, Caspase-1 expressions, IL-1β and IL-18 levels were reduced in DM+Ir group. The results suggested that irbesartan may exert myocardial protection by inhibiting the expression of the NLRP3/ASC/Caspase-1 pathway in diabetic rats.","PeriodicalId":17330,"journal":{"name":"Journal of the Renin-Angiotensin-Aldosterone System","volume":"21 2","pages":"1470320320926049"},"PeriodicalIF":2.9,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1470320320926049","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37983429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of the Renin-Angiotensin-Aldosterone System

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀